Literature DB >> 22185991

A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).

Hiroaki Shimizu1, Tsuyoshi Monden, Takanori Tomotsune, Yuki Nakatani, Nozomi Domeki, Mihoko Matsumura, Teruo Jojima, Yoshiaki Kawagoe, Kikuo Kasai.   

Abstract

A 62-year-old woman was admitted with dry mouth, general fatigue, and severe back pain. Biochemistry examination showed extreme hypercalcemia (21.2 mg/dL). Bone marrow examination was negative, but needle biopsy of a metastatic lung tumor revealed abnormal plasma cells; thus, multiple myeloma stage III-A was finally diagnosed. Serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α) were markedly elevated (PTHrP 7.2 pmol/L, normal <1.1 pmol/L; MIP-1α 84.9 pg/mL, normal <46.9 pg/mL). Her myeloma appeared to have simultaneously caused two mechanisms producing hypercalcemia: humoral hypercalcemia of malignancy (HHM) by PTHrP and local osteolytic hypercalcemia (LOH) by MIP-1α. Therefore, the combination of two calcium-modulating abnormalities likely aggravated her hypercalcemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22185991     DOI: 10.2169/internalmedicine.50.6096

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  TGF-β Stimulates Endochondral Differentiation after Denervation.

Authors:  Ye Li; Austin Y Tian; Jennifer Ophene; Mason Y Tian; Zhenjiang Yao; Sidong Chen; Hongwei Li; Xiaoyan Sun; Hongyan Du
Journal:  Int J Med Sci       Date:  2017-04-08       Impact factor: 3.738

2.  Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.

Authors:  Paweł Robak; Edyta Węgłowska; Izabela Dróżdż; Damian Mikulski; Dariusz Jarych; Magdalena Ferlińska; Ewa Wawrzyniak; Małgorzata Misiewicz; Piotr Smolewski; Wojciech Fendler; Janusz Szemraj; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2020-06-06       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.